In this issue of the BJD, Neil Korman has published an interesting review article presenting the evidence supporting psoriasis as a systemic disease. He also discusses new psoriasis treatment paradigms, which may potentially reduce the effects of systemic inflammation and consequently prevent or reverse comorbidities.1 Optimizing patient outcomes beyond clearing the skin, such as reducing the risk of cardiovascular diseases, is crucially relevant for our clinical practice. In this commentary, the pathogenesis behind the comorbidities and whether systemic treatment of psoriasis could reduce the risk of comorbidities by damping systemic inflammation will be discussed.
Does systemic treatment of psoriasis reduce the risk of comorbidities?
Gisondi, P
Conceptualization
2019-01-01
Abstract
In this issue of the BJD, Neil Korman has published an interesting review article presenting the evidence supporting psoriasis as a systemic disease. He also discusses new psoriasis treatment paradigms, which may potentially reduce the effects of systemic inflammation and consequently prevent or reverse comorbidities.1 Optimizing patient outcomes beyond clearing the skin, such as reducing the risk of cardiovascular diseases, is crucially relevant for our clinical practice. In this commentary, the pathogenesis behind the comorbidities and whether systemic treatment of psoriasis could reduce the risk of comorbidities by damping systemic inflammation will be discussed.File | Dimensione | Formato | |
---|---|---|---|
bjd0823.pdf
accesso aperto
Licenza:
Dominio pubblico
Dimensione
133.72 kB
Formato
Adobe PDF
|
133.72 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.